U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT06928389) titled 'Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer' on April 08.
Brief Summary: This is a Phase 3 Randomized, double-blind, Multicenter Study of Ivonescimab Combined with Docetaxel Versus Placebo Combined with Docetaxel in Patients with Locally advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) that has progressed on or after PD-(L)1 inhibitor-based therapy. The purpose of this study is to evaluate the efficacy and safety of ivonescimab versus placebo, combined with docetaxel in patients with advanced NSCLC.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Non-Small Cell Lu...